Description
GLP-3
GLP-3 is a commonly used informal name for retatrutide (LY3437943), an investigational synthetic peptide designed to interact with three metabolically important receptor systems: the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Unlike conventional GLP-1 receptor agonists that primarily engage one pathway, retatrutide was engineered to produce simultaneous activity across all three receptors.
The “GLP-3” terminology does not represent a third naturally occurring glucagon-like peptide in humans. Instead, it is an informal research and commercial label associated with the compound’s three-receptor mechanism. Scientific literature generally identifies the molecule as retatrutide or LY3437943.
Retatrutide has become an important subject in metabolic research because the combined activation of GLP-1, GIP, and glucagon pathways may produce a broader physiological response than single- or dual-receptor agonism. Research has investigated its effects on glucose regulation, energy metabolism, appetite-related signaling, body weight, and lipid metabolism.
Specifications
Other Known Titles: Retatrutide, LY3437943, GLP-3, GLP-3 RT
Peptide Type: Synthetic triple receptor agonist
Receptor Targets: GLP-1R, GIPR, GCGR
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: Approximately 4,731.3 g/mol
CAS Number: 2381089-83-2
GLP-3 Research
GLP-3 and Triple-Receptor Signaling
The defining feature of retatrutide is its ability to engage three hormone receptors involved in metabolic regulation. GLP-1 signaling is associated with glucose-dependent insulin secretion and appetite-related pathways, while GIP contributes to metabolic and insulin-related signaling. Glucagon, in contrast, plays an important role in energy mobilization and regulation of glucose metabolism.
Researchers developed retatrutide to combine these complementary biological pathways within a single peptide molecule. This approach is referred to as triple agonism because one compound interacts with GLP-1R, GIPR, and GCGR.
Experimental research has investigated whether simultaneous stimulation of these receptors can produce broader metabolic effects than activation of an individual pathway. This makes retatrutide particularly relevant to studies examining how multiple hormonal signals can be coordinated to influence energy balance and metabolic physiology.
GLP-3 and Glucose Metabolism
Glucose regulation is one of the major areas explored in retatrutide research. Activation of GLP-1R and GIPR can influence glucose-dependent insulin signaling, while glucagon receptor activity contributes to hepatic glucose regulation and energy mobilization.
Researchers have evaluated retatrutide in controlled clinical and experimental settings to investigate changes in glucose-related measurements. The compound’s combined receptor activity provides a model for studying whether simultaneous incretin and glucagon signaling can alter metabolic homeostasis.
The available evidence has generated substantial interest in triple-receptor agonism as a distinct approach to metabolic research. However, individual responses can vary considerably, and research findings should not be interpreted as establishing GLP-3 as an approved treatment.
GLP-3 and Energy Balance
Energy balance depends on the interaction between food intake, energy expenditure, nutrient utilization, and hormonal signaling. Because GLP-1, GIP, and glucagon participate in different aspects of this network, researchers have investigated whether combining their receptor activity may influence overall energy metabolism.
Retatrutide has been studied for its potential effects on appetite-related signaling and energy balance. Experimental findings have suggested that the compound may affect pathways involved in food intake while simultaneously influencing peripheral metabolic processes.
This multi-pathway activity distinguishes retatrutide from compounds designed to activate only GLP-1R. Researchers are continuing to investigate how the balance between incretin signaling and glucagon activity contributes to the metabolic profile observed with triple agonism.
GLP-3 and Body-Weight Research
Changes in body weight have been an important endpoint in clinical research involving retatrutide. Because the compound activates several receptors associated with appetite and metabolism, investigators have examined whether triple agonism can produce substantial alterations in body composition and body weight.
Clinical research has reported significant weight reduction in participants receiving retatrutide, generating considerable interest in the compound’s metabolic effects. The magnitude of observed changes has helped establish triple-receptor agonism as an important area of ongoing pharmaceutical research.
These results represent findings from clinical investigations of retatrutide and should not be attributed to a separate naturally occurring “GLP-3” hormone. The correct scientific identity of the investigational molecule is retatrutide (LY3437943).
GLP-3 and Lipid Metabolism
Beyond glucose and body weight, retatrutide has been investigated for its possible influence on lipid and energy metabolism. Glucagon receptor activation is particularly relevant because glucagon participates in the mobilization and utilization of stored energy.
Researchers have therefore explored whether the combined GLP-1/GIP/glucagon activity of retatrutide may influence circulating lipid parameters and broader metabolic markers.
The triple-agonist design provides an experimental framework for studying how increased glucagon signaling can be combined with incretin-mediated pathways. This is an important distinction from conventional GLP-1-only approaches, where glucagon receptor activation is not part of the intended mechanism.
GLP-3 and Liver Metabolism
The liver is a major target of metabolic signaling and plays a central role in glucose production, lipid handling, and energy storage. Because glucagon receptor signaling is strongly connected to hepatic metabolism, retatrutide has also become a subject of research involving liver-related metabolic endpoints.
Investigators have examined whether triple receptor activation may influence hepatic fat accumulation and other metabolic characteristics associated with impaired energy regulation.
These studies have contributed to growing interest in retatrutide for research into metabolic dysfunction and liver-associated disorders. However, specific clinical indications and long-term outcomes remain dependent on the results of ongoing research and regulatory evaluation.
GLP-3 and Appetite Signaling
GLP-1 receptor signaling is closely associated with appetite and satiety pathways, including signaling within the central nervous system. GIP and glucagon pathways may also contribute to the broader regulation of energy intake and expenditure.
Retatrutide’s ability to activate all three receptor systems has led researchers to investigate its effects on appetite-related behavior and food intake. The compound provides an opportunity to study whether simultaneous activation of these pathways produces a different response from single-receptor agonists.
Research into these mechanisms may help clarify how peripheral metabolic signals communicate with neural systems involved in appetite regulation.
GLP-3 and Triple-Agonist Research
The development of retatrutide represents a broader shift toward multi-receptor peptide engineering. Earlier metabolic peptides were generally designed around activity at a single receptor, while later compounds incorporated activity across two or more hormonal pathways.
Retatrutide takes this strategy further by combining GLP-1, GIP, and glucagon receptor agonism within one synthetic molecule. Researchers are studying whether this coordinated activity can provide complementary effects on glucose regulation, appetite, energy expenditure, and lipid metabolism.
The compound has therefore become an important research model for understanding how multiple endocrine pathways can be manipulated simultaneously through rational peptide design.
GLP-3 Research Status
GLP-3, when used as a product name, should be distinguished from the formal scientific identity of retatrutide. There is no established human hormone formally called GLP-3; the term is primarily an informal label used in connection with triple-receptor agonist research.
Retatrutide remains an investigational compound, and research has focused on its activity at GLP-1, GIP, and glucagon receptors and its potential effects on metabolic physiology. Its clinical development does not mean that a separate “GLP-3” hormone exists.
For laboratory and scientific research, GLP-3/retatrutide is therefore best described as a synthetic triple receptor agonist peptide whose biological activity is being studied across metabolic signaling, glucose regulation, appetite, energy balance, lipid metabolism, and related physiological pathways.
There are no reviews yet.